Novartis breast cancer drug Kisqali wins EU approval
Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators.
Read More
Tag: MONALEESA-2
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
